PMID- 30101378
OWN - NLM
STAT- MEDLINE
DCOM- 20190411
LR  - 20221207
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 62
IP  - 3
DP  - 2018 Dec
TI  - The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist 
      semaglutide in patients with type 2 diabetes mellitus: a systemic review and 
      meta-analysis.
PG  - 535-545
LID - 10.1007/s12020-018-1708-z [doi]
AB  - OBJECTIVES: To investigate the safety and efficacy of once-weekly glucagon-like 
      peptide-1 (GLP-1) receptor agonist semaglutide as monotherapy or add-on to other 
      antihyperglycaemic agents (AHAs) in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: PubMed, Embase, Cochrane library and ClinicalTrials.gov were 
      searched from the inception to January 18, 2018. Randomised controlled trials 
      (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were 
      included in our meta-analysis. Risk ratio (RR) and mean difference (MD) with 95% 
      confidence intervals (CI) were used to evaluate the outcomes. RESULTS: A total of 
      11 studies with 9519 patients were included in our meta-analysis. The results 
      revealed that compared with placebo or other AHAs, semaglutide had further 
      reduced the level of haemoglobin A1c (HbA1c) [MD 1.03%, 95% CI (0.85%, 1.22%), 
      p < 0.00001], self-measured plasma glucose (SMPG) [MD 1.19 mmol/L, 95% CI 
      (0.84 mmol/L, 1.53 mmol/L), p < 0.00001], fasting plasma glucose (FPG) [MD 
      1.33 mmol/L, 95% CI (0.97 mmol/L, 1.69 mmol/L), p < 0.00001] and weight [MD 
      3.61 kg, 95% CI (3.05 kg, 4.17 kg), p < 0.00001] and significantly increased 
      participants who achieved HbA1c < 7.0% [RR 2.26, 95% CI (1.89, 2.70), 
      p < 0.00001] in T2DM patients. Semaglutide had a significant increase in the 
      incidence of adverse events (AEs) [RR 1.06, 95% CI (1.02, 1.11), p < 0.0001] and 
      an analogous incidence in serious adverse events (SAEs) [RR 0.94, 95% CI (0.86, 
      1.02), p = 0.11] and hypoglycaemic events (severe or blood glucose (BG)-confirmed 
      symptomatic) [RR 0.93, 95% CI (0.74, 1.16), p = 0.50] compared with the control 
      group. CONCLUSIONS: This article revealed that semaglutide had a favourable 
      efficacy and safety in treating T2DM patients. It maybe a superior choice for 
      T2DM patients who have obesity or a poor adherence to daily AHAs.
FAU - Li, Xuejing
AU  - Li X
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, 050051, Shijiazhuang, Hebei Province, China.
FAU - Qie, Suhui
AU  - Qie S
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, 050051, Shijiazhuang, Hebei Province, China.
FAU - Wang, Xianying
AU  - Wang X
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, 050051, Shijiazhuang, Hebei Province, China.
FAU - Zheng, Yingying
AU  - Zheng Y
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, 050051, Shijiazhuang, Hebei Province, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, 050051, Shijiazhuang, Hebei Province, China.
FAU - Liu, Guoqiang
AU  - Liu G
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, 050051, Shijiazhuang, Hebei Province, China. 
      liugq1223@sohu.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180812
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Blood Glucose)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
SB  - IM
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Glucagon-Like Peptides/*therapeutic use
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Efficacy
OT  - Meta-analysis
OT  - Safety
OT  - Semaglutide
OT  - Type 2 diabetes mellitus
EDAT- 2018/08/14 06:00
MHDA- 2019/04/12 06:00
CRDT- 2018/08/14 06:00
PHST- 2018/04/19 00:00 [received]
PHST- 2018/07/30 00:00 [accepted]
PHST- 2018/08/14 06:00 [pubmed]
PHST- 2019/04/12 06:00 [medline]
PHST- 2018/08/14 06:00 [entrez]
AID - 10.1007/s12020-018-1708-z [pii]
AID - 10.1007/s12020-018-1708-z [doi]
PST - ppublish
SO  - Endocrine. 2018 Dec;62(3):535-545. doi: 10.1007/s12020-018-1708-z. Epub 2018 Aug 
      12.